Securities code: 300705 securities abbreviation: Hunan Jiudian Pharmaceutical Co.Ltd(300705)
Announcement No.: 2022-002 bond Code: 123110 bond abbreviation: Jiudian convertible bond
Hunan Jiudian Pharmaceutical Co.Ltd(300705)
Announcement on resolutions of the 7th Meeting of the 3rd board of directors
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
1、 Convening of board meeting
The seventh meeting of the third board of directors of Hunan Jiudian Pharmaceutical Co.Ltd(300705) (hereinafter referred to as “the company”) was held on January 11, 2022 in the company’s conference room in the form of on-site communication meeting, and the meeting notice was delivered by mail on January 8, 2022. There were 7 directors who should attend the meeting, and 7 directors actually attended the meeting (including Ms. Duan Lixin, Mr. Zheng Xiahui, Ms. Yang Qiulin, Mr. Zhou Congshan and Ms. Xiang Jing by means of communication voting). Supervisors and some senior managers attended the meeting as nonvoting delegates. The meeting was convened and presided over by Mr. Zhu Zhihong, chairman of the board. The meeting was held in accordance with relevant laws, regulations and the articles of association, and the resolutions formed were legal and effective.
2、 Deliberations of the board meeting
1. The proposal on investment in the construction of high-end preparation R & D Industrial Park (phase I) was reviewed and approved;
After deliberation, the board of Directors believes that the company’s construction project of high-end preparation R & D Industrial Park (phase I) can expand the existing external preparation product line, further improve the production capacity of external preparation products, improve product quality and reduce production costs, which is in line with the company’s long-term development and future production capacity layout.
See the announcement on investment and construction of high-end preparation R & D Industrial Park (phase I) disclosed by the company on cninfo.com for details.
Voting results: 7 in favor, 0 against and 0 abstention.
2. The proposal on adjusting some investment projects with raised funds was deliberated and adopted;
After deliberation, the board of Directors believes that the adjustment of some raised investment projects is a prudent decision made by comprehensively considering the company’s development plan, actual operation, internal and external environment and other factors. The appropriate adjustment of raised investment projects is more reasonable and effective, which meets the company’s development plan and actual needs.
For details, see the announcement on adjusting some investment projects with raised funds disclosed by the company on cninfo.com. The independent opinions issued by the independent directors of the company and the special verification opinions on the adjustment of some raised capital investment projects issued by Western Securities Co.Ltd(002673) were published on cninfo.com on the same day. Voting results: 7 in favor, 0 against and 0 abstention.
3. The proposal on joint investment and related party transactions with professional investment institutions was deliberated and adopted;
After deliberation, the board of Directors believes that this joint investment with professional institutions is to expand investment channels, cultivate new technologies and new businesses with synergistic effects with the main business, improve the comprehensive competitiveness of the company and promote the continuous development and growth of the company on the premise of ensuring the development of the company’s main business and relying on the industry experience, management and resource advantages of professional investment institutions, Providing guarantee for sustainable and healthy development in the future is in line with the company’s development strategy and the interests of all shareholders. There are no circumstances that affect the company’s sustainable operation ability, financial status, operating results or horizontal competition, or damage the interests of shareholders of the listed company.
See the announcement on joint investment and related party transactions with professional investment institutions disclosed by the company on cninfo.com for details. The prior approval opinions and independent opinions issued by the independent directors of the company and the special verification opinions on joint investment and related party transactions between the company and professional investment institutions issued by Western Securities Co.Ltd(002673) were published on cninfo.com on the same day.
Mr. Zhu Zhihong, Ms. Duan Lixin, Mr. Zheng Xiahui and Ms. Zhu Zhiyun avoided voting on the proposal as related persons.
Voting results: 3 in favor, 0 against and 0 abstention.
This proposal needs to be submitted to the general meeting of shareholders of the company for deliberation.
4. The proposal on convening the first extraordinary general meeting of shareholders in 2022 was considered and adopted.
After deliberation, the board of directors agreed that the company would hold the first extraordinary general meeting of shareholders in 2022 in the company’s conference room (No. 1, Jiankang Avenue, Liuyang economic and Technological Development Zone, Changsha) at 14:30 on January 26, 2022. See the notice on convening the first extraordinary general meeting of shareholders in 2022 disclosed by the company on cninfo.com for details.
Voting results: 7 in favor, 0 against and 0 abstention.
3、 Documents for future reference
1. Resolutions of the 7th Meeting of the 3rd board of directors of the company; 2. Prior approval opinions of independent directors on joint investment and related party transactions with professional investment institutions; 3. Independent opinions of independent directors on matters related to the seventh meeting of the third board of directors. It is hereby announced.
Hunan Jiudian Pharmaceutical Co.Ltd(300705) board of directors January 12, 2021
